The anti-angiogenic effects of oxymatrine on human pancreatic cancer were confirmed in pancreatic cancer in vitro and in vivo, via regulating the activity of the NF-κB-mediated VEGF signaling pathway. This evidence concerns the gene NFKB1 and pancreatic neoplasm.